Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...
In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...
Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. The authors have no ...
In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
The Organoid group at the Hubrecht Institute has identified a new link between FBXW7 mutations and epidermal growth factor receptor (EGFR) signaling activity. The FBXW7 gene is commonly mutated in ...
Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...
The relation between body mass index, comorbidity, choice of surgery, and prognostic factors in early breast cancer: Data from a nation-wide Danish cohort No significant financial relationships to ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results